Clinical trials: B-Cell Pediatric ALL
B Cell Leukemia
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR).
- Trial name
- NCT01683279
- Testing
- Autologous CD19 CAR+ EGFTt + T cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Seattle Children's Hospital
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
B-cell Acute Lymphoblastic Leukemia
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric…
- Trial name
- NCT06080191
- Testing
- CD19-CAR_Lenti_ALLO
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
- Trial name
- PALL (NCT02808442)
- Testing
- UCART19
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 13 people
- Sponsor
- Institut de Recherches Internationales Servier
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
B-Cell Leukemia, B-Cell Lymphoma
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Clinical studies of CD19 CAR-T cells in the treatment of blood and lymphatic system tumors have achieved unprecedented successes.
- Trial name
- NCT03098355
- Testing
- 4SCAR19/22 T cells, Interleukin-2
- Where
- China
- Sponsor
- Zhujiang Hospital
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis
- Trial name
- NCT00101270
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, in Relapse
Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or…
- Trial name
- CARCIK (NCT03389035)
- Testing
- CARCIK-CD19
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia
Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL.
- Trial name
- NCT07313592
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Neuroblastoma, Sarcoma
Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill tumor cells.
- Trial name
- NCT00101309
- Testing
- aldesleukin, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia)
PRAISE-IR Versus CIBMTR Controls
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07717164
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Miltenyi Biomedicine GmbH
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Trial name
- HEM-iSMART E (NCT07175415)
- Testing
- Capivasertib, Venetoclax, Dexamethasone
- Volunteers
- 42 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
An historical data comparator study for children with relapsed/refactory acute lymphoblastic leukemia (ALL).
- Trial name
- NCT02303522
- Testing
- Other: not applicable - observational study
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 207 people
- Sponsor
- Amgen
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric…
- Trial name
- NCT04544592
- Testing
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01625143
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
B-cell NHL, CLL
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
This is a single arm, open-label, multi-center, phase I/II study to determine the engraftment, safety and clinical activity of allogeneic CARCIK-CD19 cells in adult and pediatric patients with relapsed/refractory mature B-cell…
- Trial name
- NCT05869279
- Testing
- CARCIK-CD19
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Systemic Aspergillosis, Systemic Candidiasis
Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic…
- Trial name
- NCT01040156
- Where
- Germany
- Sponsor
- University Children's Hospital Tuebingen